Nantes / Paris / France, 19th of June, 2018 – In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies, BioNet-Asia (BNA), an innovative vaccine developer, and the research team led by Dr. Anavaj Sakuntabhai at the Functional Genetics of Infectious Diseases Unit, Institut Pasteur Paris France, (GFMI-IP), announce today the promising development of Nanotaxi formulated DNA vaccine to induce strong immune response against dengue virus
Under this collaboration, ICA, thanks to Nanotaxi designed to unlock the promise of nucleic acids to treat diseases, and Dr. Sakuntabhai, with his expertise on genetic susceptibility to mosquito-borne infection, created a single component pentavalent dengue-Zika vaccine preventing antibody-dependent enhancement phenomenon. This project has been selected to be funded by the Scientific Council of the Southeast Asia-Europe Joint Funding Scheme and was praised for its vision, and expert team.
A monovalent DNA/Nanotaxi vaccine was tested in the first instance for the evaluation of immune response against various epitopes of dengue virus.
For low-dose and mono- or multivalent vaccine design, the delivery method uses Nanotaxi, which can deliver genetic material directly into the cytosol to increase dramatically gene expression and elicit very strong innate immune responses.
Under this collaborative effort, and with the financial supports from Agence Nationale de la Recherche – France (ANR), Thailand Center of Excellence for Life Sciences (TCELS), ICA, BNA, Institut Pasteur Cambodia, and Chulalongkorn university (Thailand), will continue the candidate development to optimize antigen compositions to induce broadly cross-reactive immune responses for Zika and dengue viruses while preventing antibody-dependent enhancement phenomenon by a patented approach.
Contacts:
In-Cell-Art
Tel: 33 (0)6 73 19 12 02
E-mail: info@incelllart.com
http://www.incellart.com
Institut Pasteur press office
Myriam Rebeyrotte – 33 (0)1 45 68 81 01
Aurelie Perthuision – 33 (0)1 45 68 89 28
presse@pasteur.fr
BioNet-Asia
Mr Laurent Dapremont
Director Strategic Business Development
E-mail: laurent.d@bionet-asia.com
Tel: +61 (04) 1362 0839
www.bionet-asia.com
